

Britta Weber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5793274/publications.pdf>

Version: 2024-02-01

26
papers

729
citations

758635

12
h-index

580395

25
g-index

27
all docs

27
docs citations

27
times ranked

1589
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. <i>Acta Oncologica</i> , 2022, 61, 197-201.	0.8	2
2	Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. <i>Acta Oncologica</i> , 2022, 61, 277-285.	0.8	6
3	Survival and morbidity following stereotactic radiotherapy of hepatocellular carcinoma: a ten-year, single institution experience. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 259-265.	0.6	1
4	Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 376.	1.1	7
5	Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. <i>Pancreas</i> , 2021, 50, 685-695.	0.5	4
6	Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring. <i>BMC Cancer</i> , 2021, 21, 494.	1.1	5
7	Uniform versus non-uniform dose prescription for proton stereotactic body radiotherapy of liver tumors investigated by extensive motion-including treatment simulations. <i>Physics in Medicine and Biology</i> , 2021, 66, 205009.	1.6	3
8	A national study on the inter-observer variability in the delineation of organs at risk in the brain. <i>Acta Oncologica</i> , 2021, 60, 1548-1554.	0.8	10
9	Treatment plan comparison of proton vs photon radiotherapy for lower-grade gliomas. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 20, 98-104.	1.2	4
10	A Randomized Controlled Trial of Emotion Regulation Therapy for Psychologically Distressed Caregivers of Cancer Patients. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz074.	1.4	20
11	Pilot Study Experiences With Hyperpolarized [¹³ C]pyruvate MRI in Pancreatic Cancer Patients. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 961-963.	1.9	45
12	TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1433-1440.	0.6	28
13	Hepatic regeneration following radiation-induced liver injury is associated with increased hepatobiliary secretion measured by PET in Göttingen minipigs. <i>Scientific Reports</i> , 2020, 10, 10858.	1.6	4
14	Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. <i>European Journal of Cancer</i> , 2020, 129, 50-59.	1.3	17
15	First clinical real-time motion-including tumor dose reconstruction during radiotherapy delivery. <i>Radiotherapy and Oncology</i> , 2019, 139, 66-71.	0.3	21
16	A Prospective Cohort Study of Gated Stereotactic Liver Radiation Therapy Using Continuous Internal Electromagnetic Motion Monitoring. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 366-375.	0.4	43
17	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. <i>BMC Cancer</i> , 2018, 18, 191.	1.1	14
18	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib. <i>Lung Cancer</i> , 2016, 100, 77-84.	0.9	97

#	ARTICLE	IF	CITATIONS
19	Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2016, 127, 525-533.	1.4	11
20	Outcomes of Proton Beam Radiotherapy for Large Non-Peripapillary Choroidal and Ciliary Body Melanoma at TRIUMF and the BC Cancer Agency. <i>Ocular Oncology and Pathology</i> , 2016, 2, 29-35.	0.5	19
21	Early and late brain metastases in EGFR wild type and EGFR mutation positive non small cell lung cancer: Implications for survival.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19065-e19065.	0.8	0
22	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitorâ€sensitizing and resistance mutations in the plasma DNA of patients with advanced nonâ€small cell lung cancer during treatment with erlotinib. <i>Cancer</i> , 2014, 120, 3896-3901.	2.0	180
23	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 224-230.	0.9	41
24	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , 2014, 85, 435-441.	0.9	11
25	Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1287-1289.	0.5	124
26	Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1946-1949.	0.5	12